株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

先進国の胃腸治療薬市場:特許失効による収益減少に対抗するための、新薬の認証と有望なパイプライン製品

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

発行 GBI Research 商品コード 294433
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
先進国の胃腸治療薬市場:特許失効による収益減少に対抗するための、新薬の認証と有望なパイプライン製品 Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
出版日: 2014年01月27日 ページ情報: 英文
概要

先進国の胃腸治療薬の市場規模は、2012年には総額68億米ドルに上りました。また、2012〜2019年の年平均(CAGR)市場成長率はマイナス0.3%と予想されています。主な疾患別に見てみると、2012年現在の市場規模は、過敏性腸症候群(IBS)向けが7億2700万米ドル、潰瘍性大腸炎(UC)向けが22億米ドル、クローン病(CD)向けが38億米ドルとなっています。HumiraやRemicadeといった売上高の大半を占めていた医薬品の特許がまもなく失効することが、市場のマイナス成長の主な要因です。ただし、治験の最終段階にある有望なパイプライン製品の上市によって、この流れをある程度まで緩和できるものと思われます。

当レポートでは、主要先進国(米国・英国・フランス・ドイツ・イタリア・スペイン・日本・カナダ)における胃腸関連の治療薬の市場について分析し、疾患の概要・特性や、主な上市済み製品の概要、有望なパイプライン製品の情報、治験の進行状況と今後の製品上市の見通し、各国市場の動向見通し(今後6年間分)、資本取引・業務提携の主な動きなどを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 先進国の胃腸治療薬市場:イントロダクション

  • 過敏性腸症候群
  • 潰瘍性大腸炎
  • クローン病

第3章 上市済み製品(全世界)

  • 過敏性腸症候群
  • 潰瘍性大腸炎
  • クローン病
  • 主な上市済み製品
    • Amitiza
    • Humira
    • Remicade
    • Simponi
    • Cimzia
    • Tysabri

第4章 パイプライン分析

  • 過敏性腸症候群
    • パイプラインの概況
    • 分子の種類別の分析
    • 機能メカニズム別の分析
  • 潰瘍性大腸炎のパイプライン
  • クローン病のパイプライン
  • パイプライン上の有望なパイプライン候補
    • GSK-1605786
    • MLN0002
    • EMD-61753

第5章 市場予測(今後6年間分)

  • 先進国市場
    • 治療法の利用パターン
    • 年間治療費
    • 市場規模
  • 米国
  • 欧州
  • カナダ
  • 日本
  • 市場促進・抑制要因

第6章 資本取引と戦略的企業統合(全世界)

  • 資本取引の分析
  • 主な共同開発取引(全3件)
  • 主なライセンス取引(全3件)

第7章 付録

図表一覧

目次
Product Code: GBIHC318MR

GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries', which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
  • Disease overview and treatment usage patterns
  • Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
  • Major marketed products for the indication types covered
  • In-depth pipeline analysis for IBS, UC and CD
  • Key drivers and restraints that have had and are expected to have a major impact upon the market
  • Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
  • Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Gastrointestinal Therapeutics Industry: Promising Drugs in Late-Stage Development Could Stabilize Declining Global Market, says GBI Research.

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn's disease (CD) in the eight major markets (8MM) - the US, UK, France, Germany, Italy, Spain, Canada and Japan - is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 0.3%, forecasts business intelligence provider GBI Research.

According to the firm's latest report*, the GI market will register different CAGRs across the 8MM during the forecast period. The US and Japan will witness positive CAGRs of 0.2% and 4%, respectively, while the European markets will decline at a negative CAGR of 2.5%. This unfavourable growth is due to the upcoming patent expiry of various major drugs.

Arti Singh, Analyst for GBI Research, says: "As Humira and Remicade account for a substantial share of the GI therapeutics industry, their patent expiries will harm the overall market value. The entry of generics and biosimilars will also have a strong impact on sales."

However, promising pipeline drugs in the late stages of development could stabilize the current market.

Singh continues: "Three molecules in the pre-registration stage of development are expected to be approved during the forecast period. Of these molecules, one - vedolizumab - is indicated for the treatment of both UC and CD. The second molecule is a biosimilar of blockbuster drug Remicade (infliximab) and is expected to be launched following Remicade's patent expiry."

Additionally, almost 51% of the overall GI pipeline is in Phase II and Phase III development, of which 19 molecules are indicated for the treatment of IBS, 48 for UC and 41 for CD.

"The major factors currently stabilizing the market include the increasing prevalence of GI diseases, growing awareness of the importance of detecting these diseases early and the availability of effective diagnostics," the analyst concludes.

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

This report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the irritable bowel syndrome, ulcerative colitis and Crohn's disease indications in the eight major markets - the US, UK, France, Germany, Italy, Spain, Canada and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Gastrointestinal Therapeutics in Major Developed Markets - Introduction

  • 2.1. Irritable Bowel Syndrome
    • 2.1.1. Classification
    • 2.1.2. Symptoms
    • 2.1.3. Etiology
    • 2.1.4. Pathophysiology
    • 2.1.5. Diagnosis
    • 2.1.6. Epidemiology
    • 2.1.7. Prognosis
    • 2.1.8. Treatment Options
  • 2.2. Ulcerative Colitis
    • 2.2.1. Classification
    • 2.2.2. Symptoms
    • 2.2.3. Etiology
    • 2.2.4. Pathophysiology
    • 2.2.5. Diagnosis
    • 2.2.6. Epidemiology
    • 2.2.7. Prognosis
    • 2.2.8. Treatment Options
  • 2.3. Crohn's Disease
    • 2.3.1. Classification
    • 2.3.2. Symptoms
    • 2.3.3. Etiology
    • 2.3.4. Pathophysiology
    • 2.3.5. Diagnosis
    • 2.3.6. Epidemiology
    • 2.3.7. Prognosis
    • 2.3.8. Treatment Options

3. Gastrointestinal Therapeutics in Major Developed Markets - Marketed Products (Global)

  • 3.1. Irritable Bowel Syndrome
  • 3.2. Ulcerative Colitis
  • 3.3. Crohn's Disease
  • 3.4. Key Marketed Products
    • 3.4.1. Amitiza
    • 3.4.2. Humira
    • 3.4.3. Remicade
    • 3.4.4. Simponi
    • 3.4.5. Cimzia
    • 3.4.6. Tysabri

4. Gastrointestinal Therapeutics in Major Developed Markets - Pipeline Analysis

  • 4.1. Irritable Bowel Syndrome
    • 4.1.1. Overall Pipeline
    • 4.1.2. Pipeline Analysis by Molecule Type
    • 4.1.3. Pipeline Analysis by Mechanism of Action
  • 4.2. Ulcerative Colitis Pipeline
    • 4.2.1. Overall Pipeline
    • 4.2.2. Pipeline Analysis by Molecule Type
    • 4.2.3. Pipeline Analysis by Mechanism of Action
  • 4.3. Crohn's Disease Pipeline
    • 4.3.1. Overall Pipeline
    • 4.3.2. Pipeline Analysis by Molecule Type
    • 4.3.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Promising Drug Candidates in the Pipeline
    • 4.4.1. GSK-1605786
    • 4.4.2. MLN0002
    • 4.4.3. EMD-61753

5. Gastrointestinal Therapeutics in Major Developed Markets - Market Forecast to 2019

  • 5.1. Major Developed Markets
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Annual Cost of Therapy
    • 5.1.3. Market Size
  • 5.2. US
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Europe
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Canada
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Gastrointestinal Therapeutics in Major Developed Markets - Deals and Strategic Consolidations (Global)

  • 6.1. Deals Analysis
  • 6.2. Major Co-Development Deals
    • 6.2.1. AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide
    • 6.2.2. Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies
    • 6.2.3. Galapagos and AbbVie Extend GLPG0634KKKKK Development Agreement to Include Crohn's Disease
  • 6.3. Major Licensing Deals
    • 6.3.1. AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3KKKKK Inhibitor Program
    • 6.3.2. Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin
    • 6.3.3. GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx

7. Gastrointestinal Therapeutics in Major Developed Markets - Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-Registration
    • 7.1.8. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. Major Developed Markets
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. Sources
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009
  • Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009
  • Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004
  • Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007
  • Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn's Disease, 2007
  • Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011
  • Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn's Disease, 2013
  • Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn's Disease, 2012
  • Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn's Disease , 2009
  • Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013
  • Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013
  • Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013
  • Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013
  • Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013
  • Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013
  • Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013
  • Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012
  • Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn's Disease, Market Forecast, 2012-2019
  • Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 23: Gastrointestinal Therapeutics Market, US, Crohn's Disease, Market Forecast, 2012-2019
  • Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn's Disease, Market Forecast, 2012-2019
  • Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 29: Gastrointestinal Therapeutics Market, UK, Crohn's Disease, Market Forecast, 2012-2019
  • Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 32: Gastrointestinal Therapeutics Market, France, Crohn's Disease, Market Forecast, 2012-2019
  • Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn's Disease, Market Forecast, 2012-2019
  • Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn's Disease, Market Forecast, 2012-2019
  • Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn's Disease, Market Forecast, 2012-2019
  • Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007
  • Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012
  • Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012
  • Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012
  • Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012
  • Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012
  • Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012
  • Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013
  • Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013
  • Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012
  • Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013
  • Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013
  • Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013
  • Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, 2013
  • Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013
  • Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013
  • Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012-2019
  • Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012-2019
  • Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012-2019
  • Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012-2019
  • Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012-2019
  • Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013
  • Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013
  • Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 25: GBI Research Market Forecasting Model
Back to Top